Innovating Qool Antibodies

Our Mission

Qoolabs is a biotech company that is dedicated to providing innovative antibody products for research, diagnostics and therapeutic drug development. Our team consists of experienced professionals who are passionate about delivering high-quality products and services.

Founded in 2012, Qoolabs has been committed to excellence with focus on delivering the best possible antibodies to our customers. With our core technology QMAb™ quick monoclonal antibody discovery platform, our mission is to provide high-quality antibody solutions empower our clients to reach their full potential and achieve their goals. The QMAb™ platform is designed with extensibility in mind, making it highly customizable to meet the unique needs of each of our clients. Whether you’re searching for antibodies to a small molecule or a large complex, Qoolabs has a solution that can help you to advance your research.

We take pride in our culture of innovation and collaboration, and we believe that this is what sets us apart in the marketplace. If you’re looking for a partner that can help you achieve your goals, we’d love to hear from you.


The QMAb™ (Quick Monoclonal Antibody from Blood) platform technology enables efficient cloning of antibody light and heavy chain coding DNA from B cells in peripheral blood. Using QMAb™, antibodies have been successfully generated from the blood of rabbits, chickens, and llamas, including single domain VHH nanobodies. This method has demonstrated robustness and speed in generating novel monoclonal antibodies against a wide range of target molecules. For more information on QMAb™, please see our services.


Since its inception in 2012, Qoolabs has been dedicated to providing superior products and services to our customers. We recognize that our employees are the key to achieving our goals and driving our company’s growth. Qoolabs is committed to offering our employees ongoing opportunities for professional development and personal growth. Our employees are encouraged to pursue both individual and team goals, which helps to foster a positive and collaborative work environment. Our goal is to establish a supportive culture of learning and development that enables all employees to advance their careers with us. We empower our employees to pursue their passions, identify new opportunities, and pursue innovative ideas that align with our commitment to quality and innovation.
Contact us for current job openings.


Our commitment to innovation is deeply ingrained in our company’s core values. This is exemplified by our track record of achieving multiple SBIR (Small Business Innovation Research) grants and contracts from the National Institute of Health (NIH) and the Center for Disease Control and Prevention (CDC). We were able to leverage our innovative technology to develop new antibody reagents with great potential for use in research and diagnostics. The following is a comprehensive list of the grants and contracts we have been awarded in recent years.

Award Type Agency Title Period
SBIR Phase I contract NIAID Affinity Reagents for the Immune System of Swine 09/30/2022 – 09/29/2024
SBIR Phase I contract NIAID Affinity Reagents for the Immune System of Golden Hamster 09/30/2022 – 09/29/2024
SBIR Phase I contract NCI Rapid At-Home Detection for Serologic Status of HCV Infection 09/19/2022 – 09/18/2023
SBIR Phase I contract NIAID Point-of-Care HCV Core Antigen Detection 08/31/2021 – 09/01/2022
SBIR Phase I contract NIAID Affinity Reagents for the Immune System of Guinea Pigs 08/01/2021 – 07/31/2022
RADx Subaward through UC-CAI NIH Point-of-Care Antigen Detection for SARS-COV-2 from Saliva 09/01/2020 – 08/31/2021
SBIR Phase I contract NIAID Affinity Reagents for the Immune System of Guinea Pigs 07/01/2020 – 06/30/2021
SBIR Phase I contract NCI Point of Care Diagnostics for Liver Flukes Opisthorchis viverrini and Clonorchis sinensis 09/16/2019 – 09/15/2020
SBIR Phase I contract CDC Developing Species-Specific Human Taeniasis Coproantigen Detection Immunoassays 09/16/2018 – 09/15/2019
SBIR Phase II contract CDC Immunoassay for Serological detection and quantification of Hepatitis B core antigen 09/05/2017 – 09/04/2019
SBIR Phase I contract NIAID Rapid Point of Care Detection for Serologic Status of Individuals for CMV and HSV Infection 08/01/2017 – 07/31/2018
SBIR Phase II contract CDC Rapid test for HCV core antigen 09/28/2015 – 09/30/2017
SBIR Phase I grant NHLBI Immunoaffinity Lateral Flow Assay Device for Diagnosis of Sickle Cell Disease 08/06/2014 – 06/30/2016
SBIR Phase I contract CDC Rapid test for HCV core antigen 09/30/2014 – 03/30/2015

ISO17025 Accredited laboratory

Qoolabs’ commitment to reliability, repeatability, and stability of our processes and results has allowed us to serve our customers with competence across various industries. Qoolabs has demonstrated our expertise and professionalism. Our dedication to quality in laboratory testing and analytical services has led to our accreditation as an ISO 17025 laboratory. This accreditation recognizes Qoolabs as a leader in the antibody engineering and services sector. The company’s commitment to meeting international standards and providing the highest quality services is evident in this accomplishment. Clients can have confidence in the reliability of Qoolabs’ results.


Contact Us


1915 Aston Ave
Carlsbad, CA 92008


info <at>


(858) 348-0988

Write To Us